Where does Norlase ApS rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Norlase ApS ranks #42,008 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Norlase ApS hold?

Norlase ApS holds 6 US utility patents granted between 2021 and 2025, spanning 8 technology areas.

What is Norlase ApS's Innovation Score?

Norlase ApS has an Innovation Score of 43.7 out of 100 (top 28% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Norlase ApS's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Norlase ApS.

What does claim depth mean for Norlase ApS's patents?

Norlase ApS's patents average 22.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Norlase ApS patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Norlase ApS

Q: What technology areas does Norlase ApS focus on?

Norlase ApS's top technology area is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs) with 6 patents, ranking #1,036 of 3,082 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

USPTO PatentsView assignee record - 6 granted patents across 8 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Norlase ranks #42,008 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 8 technology areas.

#42,008
of 49,997 US assignees by volume: Top 28%
by Innovation Score (43.7/100): 22.7
avg claims per patent

USPTO PatentsView assignee plate

Corpus R42008 · Foreign Corporation #42,008 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 6 grants
LOWER-Q #42,008/49,997
PHOTO-FINISH Nittany Solutions…
CPC-NARROW A61F · 8 areas
INNOV-PAR 43.7/100
CLAIMS-DENSE 22.7 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2021–2025 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Nittany Solutions Group, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Norlase’s 43.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (15%) Velocity 13.3 pts (31%) Breadth 10.0 pts (23%) Claim depth 13.6 pts (31%)

Qualcomm Incorporated · highest

85
Norlase ApS · this assignee

44
3D Lighting… · lowest

7

What this shows Norlase's Innovation Score is 43.7/100 (top 28% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Norlase?

Each dot is one of Norlase’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Norlase’s own 22.7 claims/patent is ABOVE the 13.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Norlase vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Norlase's grants concentrate

Norlase ApS is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). By volume, Norlase sits between Nittany Solutions Group, LLC and North American Manufacturing Enterprises.

Norlase's three-year grant acceleration

Norlase ApS shows 2 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Nittany Solutions…

6
Noble Research In…

6
Norbar Torque Too…

6
Norcros Group (Ho…

6
Normark Innovatio…

6
Noroo IC

6
Nortek Global Hvac

6
North American Ma…

6
Norlase Aps ◀

6

What this shows Norlase holds 6 patents at rank #42,009, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Norlase

By rank, the assignees closest to #42,009 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Norlase's primary technology class.

Norlase's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 28% higher than 72% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Norlase ApS patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	1	16.7%
2023	1	16.7%
2024	1	16.7%
2025partial year	3	50.0%

Which technologies does Norlase ApS patent most?

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 6

A61B - DIAGNOSIS; SURGERY; Identification 4

G10L - Speech Analysis Techniques OR Speech SYNTHESIS; Speech RECOGNITION; Speech OR Voice Processing TECHNIQUES; Speech OR Audio Coding OR Decoding 4

G06F - Electric Digital Data Processing 1

H02J - Circuit Arrangements OR Systems FOR Supplying OR Distributing Electric POWER; Systems FOR Storing Electric Energy 1

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 1

H01S - Devices Using THE Process OF Light Amplification BY Stimulated Emission OF Radiation [LASER] TO Amplify OR Generate LIGHT; Devices Using Stimulated Emission OF Electromagnetic Radiation IN Wave Ranges Other Than Optical 1

G05B - Control OR Regulating Systems IN GENERAL; Functional Elements OF Such SYSTEMS; Monitoring OR Testing Arrangements FOR Such Systems OR Elements 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Norlase ApS's patent record in context - here's where to go next.

Norlase ApS's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 100% of its portfolio - see every assignee active in that class. Explore A61F
Ranked #42,008 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Norlase ApS against Nittany Solutions Group, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.